Clinical trials
catalyst calendar across sponsors →Studies where VTRS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 observational
Held by 20 tracked-famous managers (GLENVIEW CAPITAL MANAGEMENT, LLC, Qube Research & Technologies Ltd, JANE STREET GROUP, LLC, AQR CAPITAL MANAGEMENT LLC, Man Group plc, +15 more) · FINRA short interest 4.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Dymista in Chinese AdolescentsNCT07597473Change from baseline in AM+PM combined reflective Total Nasal Symptom Score (rTNSS).Open-label · Treatment | Phase 4 | Recruiting | Drug: Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate | Allergic Rhinitis Due to Allergens | 100 | Mar 2027 | ≤ 223 d | 2026-08-17 |
| Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing SurveillanceNCT06471088observationalNumber of Participants With Adverse Events (AEs) | — | Unknown status | Drug: Dovprela | Dovprela | 100 | 2026-06-30 | — | 2024-06-24 |
| A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNCT06273254CmaxRandomized · Open-label · Health services research | Phase 1 | Unknown status | Drug: Sacubitril and Valsartan Tablets 49mg/51mg, Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg) | Bioequivalence Study | 48 | May 2024 | — | 2024-02-22 |
| A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting ConditionsNCT06266988Bioequivalence based on Cmax period (using the validated Phoenix® WinNonlin® software)Randomized · Open-label · Health services research | Phase 1 | Unknown status | Drug: Sacubitril and Valsartan Tablets 97mg/103mg, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg) | Chronic Heart Failure | 48 | Apr 2024 | — | 2024-02-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19